Zevra Therapeutics

Zevra Therapeutics

Yahoo Finance • 6 days ago

Zevra Therapeutics, Inc. GAAP EPS of $0.14 beats by $0.03, revenue of $39.7M beats by $5.82M

* Zevra Therapeutics, Inc. press release [https://seekingalpha.com/pr/20608774-zevra-reports-second-quarter-2026-financial-results-and-corporate-update] (ZVRA [https://seekingalpha.com/symbol/ZVRA]): Q2 GAAP EPS of $0.14 beats by $0.03.... Full story

Yahoo Finance • 15 days ago

Top profitable small caps trading at bargain P/E multiples during Q2 earnings

[Stock market activity shows price changes and trading movements in real time] FabrikaCr As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability... Full story

Yahoo Finance • 18 days ago

Zevra plunges on EU snub for rare disease therapy

[An arrow pointing downwards on top of a pile of US dollar bills.] * Zevra Therapeutics (ZVRA [https://seekingalpha.com/symbol/ZVRA]) lost ~30% in the premarket on Friday after an expert panel of the EU drug regulator, the European Medi... Full story

Yahoo Finance • 2 months ago

As U.S. profit margins near record highs, these small-cap stocks lead on profitability

[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data fr... Full story

Yahoo Finance • 2 months ago

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced th... Full story

Yahoo Finance • 3 months ago

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Ze... Full story

Yahoo Finance • 5 months ago

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement und... Full story

Yahoo Finance • 5 months ago

Zevra Turns Profitable In 2025 On Strong Uptake Of MIPLYFFA For Niemann-Pick Disease Type C

(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) has reported its fourth quarter and full-year 2025 financial results, marking a sharp turnaround from losses in 2024 as sales of its rare disease therapy MIPLYFFA accelerated. MIPLYFFA (Arimoclo... Full story

Yahoo Finance • 6 months ago

Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the pr... Full story

Yahoo Finance • 6 months ago

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that i... Full story

Yahoo Finance • 8 months ago

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the ap... Full story

Yahoo Finance • 9 months ago

Zevra Therapeutics, Inc. Announces CFO Transition

CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that it... Full story

Yahoo Finance • 9 months ago

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

2025 EPS of $(0.01) Q32025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEW... Full story

Yahoo Finance • 9 months ago

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story

Yahoo Finance • 9 months ago

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it wil... Full story

Yahoo Finance • 11 months ago

Zevra Therapeutics rises amid takeover speculation

[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story

Yahoo Finance • 11 months ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA off... Full story

Yahoo Finance • 11 months ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLY... Full story

Yahoo Finance • 11 months ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four p... Full story

Yahoo Finance • 12 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story